fda deadline semaglutide FDA's Removal of and the Evolving Tirzepatide Decisions: What Compounders Need to Know FDA Issues 'Serious Violations' Warning

The Phase 3 ATTAIN-1 trial had good results that led to this approval, but not all positive: 12.4% average weight loss (27.3 lbs) at highest dose Lower than the 15-20% weight loss seen with injectables Wegovy and Zepbound Nearly 1/4 of participants on the highest dose reported vomiting Vomiting rates are much higher than injectable GLP-1s However, there is likely a niche for Foundayo (along with the pill version of Wegovy) due to convenience: No refrigeration requirements or injection site reactions Eliminates barriers for patients avoiding injectables due to stigma, needle aversion, or storage constraints It's possible we could see this as a "maintenance" therapy after an initial injectable course

At the same time, both Lilly and Novo Nordisk made multi-billion dollar capital investments in expanding their manufacturing capacity to satisfy unrelenting patient demand, including pharmas largest M&A deal of the year, the $16.5Bn acquisition of CDMO Catalent by Novo Holdings, the controlling shareholder of Novo Nordisk

Discover effective weight loss solutions in Ranchita, CA with Semaglutide

Youll gain balanced, up-to-date insights into the science, the benefits and drawbacks, and the broader context, including what may come next in the field of weight-related treatments

In this episode, we explore the use of GLP-1 therapy for weight management beyond diabetes, including who may benefit and who should avoid it.

CSK&D is conducting an active class action investigation pertaining to oral tirzepatide drops sold by Willow Health.